论文部分内容阅读
近年来,急性冠脉综合征(ACS)的发病率呈上升趋势,ACS发病基础是动脉粥样硬化,动脉硬化斑块的破裂、出血及血栓形成导致发病,其中炎症反应、氧化应激反应均参与发病过程。普罗布考做为降脂药物已在临床广泛使用,但对ACS抗氧化、抗炎作用研究并不多。本文通过观察普罗布考对ACS患
In recent years, the incidence of acute coronary syndrome (ACS) is on the rise. The pathogenesis of ACS is atherosclerosis, atherosclerotic plaque rupture, hemorrhage and thrombosis leading to the onset of inflammation, and oxidative stress Participation in the pathogenesis. Probucol as a lipid-lowering drug has been widely used in clinical practice, but the anti-oxidant and anti-inflammatory effects of ACS are not many. This article probed probucol for ACS